Welcome to our dedicated page for AMARIN PLC\UK SEC filings (Ticker: AMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AMARIN PLC\UK's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AMARIN PLC\UK's regulatory disclosures and financial reporting.
Amarin Corporation plc filed a current report to note that it has released a press release with its preliminary unaudited 2025 financial highlights. The release also summarizes key operational accomplishments for 2025 and outlines the company’s priorities for 2026. This information is being furnished as an exhibit rather than filed, which limits how it is incorporated into other regulatory documents.
Amarin Corporation’s EVP and Chief Operating Officer, Keenan David Paul, reported routine equity compensation activity. On January 2, 2026, 3,688 Restricted Stock Units vested into the right to receive American Depositary Shares at an exercise price of $0.00. These were reflected as 3,688 American Depositary Shares acquired through an option exercise transaction.
To cover tax obligations related to the vesting, the company withheld 1,926 American Depositary Shares at a price of $13.96 per share, which the filing notes was not a market sale. After these transactions, the executive directly owned 9,712 American Depositary Shares and 3,688 RSUs. The filing also reminds investors that one ADS currently represents twenty ordinary shares following an earlier ADS ratio change.
Amarin Corporation EVP and Chief Scientific Officer Steven B. Ketchum reported equity compensation activity involving American Depositary Shares (ADSs) and restricted stock units (RSUs). On January 2, 2026, 3,688 RSUs were credited at an exercise price of $0, each representing a contingent right to receive twenty ordinary shares or cash. The same day, 3,688 ADS were acquired in a transaction coded "M," leaving 41,038 ADS directly held.
A separate transaction coded "F" shows 2,041 ADS withheld at $13.96 per ADS to cover tax liabilities tied to the vesting, reducing directly held ADS to 38,997. These RSUs were part of a 7,376‑unit grant awarded on January 10, 2025 under Amarin’s 2020 Stock Incentive Plan, scheduled to vest 50% on January 2, 2026 and the remainder on July 1, 2026. The company had previously changed its ADS ratio so that one ADS represents twenty ordinary shares, and all reported amounts reflect this ratio.
Amarin Corporation plc (AMRN) — Initial insider ownership filed. The company’s EVP and Chief Operating Officer filed a Form 3 as of 10/17/2025, reporting 7,950 American Depositary Shares (ADS) held directly.
Reported derivative holdings include Restricted Stock Units covering 6,740, 5,800, and 7,376 ADS, and stock options for 33,193 ADS at $12.4 expiring 01/10/2035, 20,900 ADS at $24.2 expiring 02/01/2034, 13,480 ADS at $36 expiring 02/21/2033, and 5,000 ADS at $29 expiring 06/01/2032. The filing notes an April 11, 2025 ADS ratio change where 1 ADS represents 20 Ordinary Shares, with equity awards adjusted accordingly. RSU and option grants vest on schedules described, generally in annual or quarterly tranches over 18 months to four years.
Amarin Corporation plc reported Q3 2025 results. Total revenue was $49.7 million (up from $42.3 million a year ago), driven by product revenue of $48.6 million and licensing and royalty revenue of $1.1 million. The company posted a net loss of $7.7 million, a significant improvement from a $25.1 million loss in Q3 2024, as operating expenses declined, particularly selling, general and administrative costs.
Gross margin was $22.2 million on cost of goods sold of $27.5 million. Amarin recorded $9.4 million of restructuring expense in the quarter and $32.2 million year‑to‑date tied to its June 24, 2025 global restructuring plan associated with its Recordati agreement, with expected total charges of $30.0–$37.0 million, substantially all cash.
Liquidity remains solid with $122.8 million in cash and cash equivalents and $163.8 million in short‑term investments as of September 30, 2025, and no outstanding debt. Year‑to‑date, revenue was $164.4 million and net loss $37.6 million. U.S. product revenue led the quarter at $40.9 million, with Europe at $4.1 million and Rest of World at $3.6 million.
Amarin Corporation plc furnished a Form 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025 and 2024.
The press release is included as Exhibit 99.1. The information is furnished under Item 2.02 and is not deemed filed under Section 18 of the Exchange Act, except as specifically incorporated by reference in future filings.
Amarin Corporation plc appointed David Keenan, Ph.D., 58, as Executive Vice President and Chief Operating Officer, effective October 17, 2025. He previously served as EVP, Technical Operations and President of Europe, having joined Amarin in May 2022 to lead manufacturing, supply chain, technical operations, and quality.
The company stated there is no change to Dr. Keenan’s compensation with this appointment. Amarin also disclosed there are no arrangements or understandings tied to his selection, no family relationships with directors or executives, and no related party interests requiring disclosure.
This Form 4 reports routine equity activity by Amarin Corp. (AMRN) SVP & CFO Peter L. Fishman on 1 Aug 2025 following the 1-for-20 ADS ratio adjustment implemented 11 Apr 2025. Fishman acquired 312 American Depositary Shares (ADS) upon the partial vesting of 2022-granted RSUs (transaction code M). To cover withholding taxes, the company retained 160 ADS at an imputed price of $14.52 (code F). After the net settlement, Fishman’s direct holding stands at 3,988 ADS (≈79,760 ordinary shares).
The RSU grant originally comprised 1,250 units vesting in four equal tranches from 2023-2026; the 2025 installment is reflected here. No open-market buying or selling occurred, and no derivative positions were closed or written. The filing signals continued insider ownership but is operationally neutral with no implications for Amarin’s fundamentals or guidance.